Skip to main content

Main menu

  • Home
  • Content
    • First Release
    • Current
    • Archives
    • Collections
    • Audiovisual Rheum
    • COVID-19 and Rheumatology
  • Resources
    • Guide for Authors
    • Submit Manuscript
    • Payment
    • Reviewers
    • Advertisers
    • Classified Ads
    • Reprints and Translations
    • Permissions
    • Meetings
    • FAQ
    • Policies
  • Subscribers
    • Subscription Information
    • Purchase Subscription
    • Your Account
    • Terms and Conditions
  • About Us
    • About Us
    • Editorial Board
    • Letter from the Editor
    • Duncan A. Gordon Award
    • Privacy/GDPR Policy
    • Accessibility
  • Contact Us
  • JRheum Supplements
  • Services

User menu

  • My Cart
  • Log In

Search

  • Advanced search
The Journal of Rheumatology
  • JRheum Supplements
  • Services
  • My Cart
  • Log In
The Journal of Rheumatology

Advanced Search

  • Home
  • Content
    • First Release
    • Current
    • Archives
    • Collections
    • Audiovisual Rheum
    • COVID-19 and Rheumatology
  • Resources
    • Guide for Authors
    • Submit Manuscript
    • Payment
    • Reviewers
    • Advertisers
    • Classified Ads
    • Reprints and Translations
    • Permissions
    • Meetings
    • FAQ
    • Policies
  • Subscribers
    • Subscription Information
    • Purchase Subscription
    • Your Account
    • Terms and Conditions
  • About Us
    • About Us
    • Editorial Board
    • Letter from the Editor
    • Duncan A. Gordon Award
    • Privacy/GDPR Policy
    • Accessibility
  • Contact Us
  • Follow jrheum on Twitter
  • Visit jrheum on Facebook
  • Follow jrheum on LinkedIn
  • Follow jrheum on YouTube
  • Follow jrheum on Instagram
  • Follow jrheum on RSS

DISEASE-MODIFYING ANTIRHEUMATIC DRUGS

  • You have access
    Canadian Adalimumab Postmarketing Observational Epidemiological Study Assessing Effectiveness in Psoriatic Arthritis (COMPLETE-PsA): 12-month Results of Comparative Effectiveness of Adalimumab and nbDMARDs
    Majed M. Khraishi, Valencia P. Remple, Samuel Silverberg, Jacqueline C. Stewart, Brandusa Florica and Louis Bessette
    The Journal of Rheumatology May 1 2022, 49 (5) 454-464; DOI: https://doi.org/10.3899/jrheum.200609
  • Open Access
    Radiographic Progression of Structural Joint Damage Over 5 Years of Baricitinib Treatment in Patients With Rheumatoid Arthritis: Results From RA-BEYOND
    Désirée van der Heijde, Cynthia E. Kartman, Li Xie, Scott Beattie, Douglas Schlichting, Daojun Mo, Patrick Durez, Yoshiya Tanaka and Roy Fleischmann
    The Journal of Rheumatology February 1 2022, 49 (2) 133-141; DOI: https://doi.org/10.3899/jrheum.210346
  • You have access
    Persistence to Biologic Therapy Among Patients With Ankylosing Spondylitis: An Observational Study Using the OPAL Dataset
    Hedley Griffiths, Tegan Smith, Christopher Mack, Jo Leadbetter, Belinda Butcher, Mustafa Acar and Sabina Ciciriello
    The Journal of Rheumatology February 1 2022, 49 (2) 150-156; DOI: https://doi.org/10.3899/jrheum.201551
  • You have access
    Anti-interleukin 6 Therapy Effect for Refractory Joint and Skin Involvement in Systemic Sclerosis: A Real-world, Single-center Experience
    Stylianos T. Panopoulos, Maria G. Tektonidou, Vasiliki-Kalliopi Bournia, Aikaterini Arida and Petros P. Sfikakis
    The Journal of Rheumatology January 1 2022, 49 (1) 68-73; DOI: https://doi.org/10.3899/jrheum.210273
  • You have access
    Effectiveness of a Second Biologic After Failure of a Non–tumor Necrosis Factor Inhibitor As First Biologic in Rheumatoid Arthritis
    Katerina Chatzidionysiou, Merete Lund Hetland, Thomas Frisell, Daniela Di Giuseppe, Karin Hellgren, Bente Glintborg, Dan Nordström, Ritva Peltomaa, Kalle Aaltonen, Nina Trokovic, Eirik K. Kristianslund, Tore K. Kvien, Sella A. Provan, Bjorn Gudbjornsson, Gerdur Grondal, Lene Dreyer, Lars Erik Kristensen, Tanja Schjødt Jørgensen, Lennart T.H. Jacobsson and Johan Askling
    The Journal of Rheumatology October 1 2021, 48 (10) 1512-1518; DOI: https://doi.org/10.3899/jrheum.201467
  • You have access
    Absence of Association Between Abatacept Exposure and Initial Infection in Patients With Juvenile Idiopathic Arthritis
    Nicolino Ruperto, Hermine I. Brunner, Nikolay Tzaribachev, Gabriel Vega-Cornejo, Ingrid Louw, Rolando Cimaz, Jason Dare, Graciela Espada, Enrique Faugier, Manuel Ferrandiz, Valeria Gerloni, Pierre Quartier, Clovis Artur Silva, Linda Wagner-Weiner, Yash Gandhi, Julie Passarell, Marleen Nys, Robert Wong, Alberto Martini and Daniel J. Lovell for the Pediatric Rheumatology Collaborative Study Group (PRCSG) and the Paediatric Rheumatology International Trials Organisation (PRINTO)
    The Journal of Rheumatology July 1 2021, 48 (7) 1073-1081; DOI: https://doi.org/10.3899/jrheum.200154
  • You have access
    Relationship Between Depression and Disease Activity in United States Veterans With Early Rheumatoid Arthritis Receiving Methotrexate
    Alan M. Rathbun, Bryant R. England, Ted R. Mikuls, Alice S. Ryan, Jennifer L. Barton, Michelle D. Shardell and Marc C. Hochberg
    The Journal of Rheumatology June 1 2021, 48 (6) 813-820; DOI: https://doi.org/10.3899/jrheum.200743
  • You have access
    Effect on Costs and Quality-adjusted Life-years of Treat-to-target Treatment Strategies Initiating Methotrexate, or Tocilizumab, or Their Combination in Early Rheumatoid Arthritis
    Maxime M.A. Verhoeven, Janneke Tekstra, Jacob M. van Laar, Attila Pethö-Schramm, Michelle E.A. Borm, Johannes W.J. Bijlsma, Johannes W.G. Jacobs, Floris P.J.G. Lafeber and Paco M.J. Welsing
    The Journal of Rheumatology April 1 2021, 48 (4) 495-503; DOI: https://doi.org/10.3899/jrheum.200067
  • You have access
    Improving Hydroxychloroquine Dosing and Toxicity Screening at a Tertiary Care Ambulatory Center: A Quality Improvement Initiative
    Sahil Koppikar, Stephanie Gottheil, Chandra Farrer and Natasha Gakhal
    The Journal of Rheumatology January 1 2021, 48 (1) 138-144; DOI: https://doi.org/10.3899/jrheum.191265
  • You have access
    Reasons for Biologic and Targeted Synthetic Disease-modifying Antirheumatic Drug Cessation and Persistence of Second-line Treatment in a Rheumatoid Arthritis Dataset
    Peter Youssef, Bruno Marcal, Peter Button, Matt Truman, Paul Bird, Hedley Griffiths, Lynden Roberts, Kathleen Tymms and Geoff Littlejohn
    The Journal of Rheumatology August 1 2020, 47 (8) 1174-1181; DOI: https://doi.org/10.3899/jrheum.190535

Pages

  • Next
  • 1
  • 2
  • 3
  • 4
  • 5

Content

  • First Release
  • Current
  • Archives
  • Collections
  • Audiovisual Rheum
  • COVID-19 and Rheumatology

Resources

  • Guide for Authors
  • Submit Manuscript
  • Author Payment
  • Reviewers
  • Advertisers
  • Classified Ads
  • Reprints and Translations
  • Permissions
  • Meetings
  • FAQ
  • Policies

Subscribers

  • Subscription Information
  • Purchase Subscription
  • Your Account
  • Terms and Conditions

More

  • About Us
  • Contact Us
  • My Alerts
  • My Folders
  • Privacy/GDPR Policy
  • RSS Feeds
The Journal of Rheumatology
The content of this site is intended for health care professionals.
Copyright © 2022 by The Journal of Rheumatology Publishing Co. Ltd.
Print ISSN: 0315-162X; Online ISSN: 1499-2752
Powered by HighWire